It isn’t unusual for oncology stocks to double in a single day after a company announces clinical trial results. Arqule (NASDAQ: ARQL) stands out among its peers because it notched a 67% gain after reporting a partial remission for just one leukemia patient.
Have investors, who have been encouraged by surging global oncology sales, lost their collective minds, or does it really look like Arqule has a winner on its hands? Let’s weigh the potential in this company’s pipeline against the risk of failure to find out.
The eyes of Ben Franklin on a $100 bill peeking out under a lot of